ARTV
Artiva Biotherapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Artiva Biotherapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Fund move
Fund move
Artiva Biotherapeutics, Inc.
4.19
No thesis.
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | RA Capital ManagementRA Capital Management | $174.2M | 44.47% | +82.23% | |
| 2 | Viking Global InvestorsViking Global Investors | $25.3M | 6.45% | new | |
| 3 | Blackstone GroupBlackstone | $23.3M | 5.95% | new | |
| 4 | 5AM Venture Management5AM Venture | $22.8M | 5.83% | 0.00% | |
| 5 | VR AdviserVR Adviser | $19.8M | 5.06% | +26.97% | |
| 6 | Franklin ResourcesFranklin Resources | $19.4M | 4.95% | +283.84% | |
| 7 | Caligan PartnersCaligan Partners | $16.8M | 4.30% | new | |
| 8 | Vanguard Capital ManagementVanguardindex-like | $9.5M | 2.43% | +372.74% | |
| 9 | Samsara BioCapitalSamsara BioCapital | $9.3M | 2.37% | new | |
| 10 | Blue Owl Capital HoldingsBlue Owl Capital | $8.5M | 2.17% | new | |
| 11 | Propel Bio ManagementPropel Bio | $6.8M | 1.72% | +375.81% | |
| 12 | BlackRockBlackRockindex-like | $6.7M | 1.72% | +225.57% | |
| 13 | Citadel AdvisorsCitadel | $5.9M | 1.51% | +3739.80% | |
| 14 | Silverarc Capital ManagementSilverarc | $5.1M | 1.30% | new | |
| 15 | Geode Capital ManagementGeodeindex-like | $3.4M | 0.88% | +247.95% | |
| 16 | Boothbay Fund ManagementBoothbay Fund | $3.0M | 0.78% | new | |
| 17 | Nantahala Capital ManagementNantahala | $2.9M | 0.74% | new | |
| 18 | Revelation Capital ManagementRevelation | $2.9M | 0.74% | 0.00% | |
| 19 | Alyeska Investment GroupAlyeska Investment | $2.7M | 0.68% | +173.62% | |
| 20 | Acuta Capital PartnersAcuta Capital Partners | $2.5M | 0.64% | new | |
| 21 | KVP Capital AdvisorsKVP Capital | $1.9M | 0.50% | new | |
| 22 | Wellington Management GroupWellington | $1.9M | 0.48% | 0.00% | |
| 23 | UBS GroupUBS | $1.8M | 0.46% | +11951.08% | |
| 24 | Seven Grand ManagersSeven Grand Managers | $1.7M | 0.43% | new | |
| 25 | State StreetState Streetindex-like | $1.6M | 0.41% | +362.72% |
72 managers report $391.6M of Artiva Biotherapeutics on form 13F for the quarter ended Jun 30 '26. 9 of them hold 80% of it; RA Capital Management is largest at 44.47%.
Largest filed tie
—
No implied move.
No implied move.
Expected move
No implied move.